Headlamp Health has announced the launch of Lumos AI, a comprehensive, intelligent platform designed to help drug developers navigate the biological and behavioural complexity that has long hindered progress in neuroscience drug development. Unlike AI tools focused on workflow automation or trial operations, Lumos AI functions as a decision-support layer, applying clinical logic and pattern recognition to biological, behavioural and clinical signals to inform decisions earlier in development.
“Mental health drug development has long operated on outdated assumptions, treating complex conditions with one-size-fits-all approaches,” said Zak Williams, Advisor for Headlamp Health. “We’re now at an inflection point where advances in technology make precision possible in a way that wasn’t even imaginable five years ago. That shift is critical to delivering the right care to the right people at the right time.”
Why neuroscience drug development trails oncology in precision
Oncology has led the shift towards precision medicine by grounding drug development in well-characterised biological markers, molecular subtypes and established responder–non-responder frameworks. In contrast, neuroscience drug development has been slower to adopt precision approaches, primarily due to the field’s inherent complexity.
Traditional approaches in neuroscience have struggled to account for patient heterogeneity, subjective symptom reporting and placebo effects, often reducing complex biology to averages that obscure individual variability. As a result, promising therapies frequently fail because trials cannot reliably identify and enrol the right patient populations or detect meaningful signals early in development.
Lumos AI addresses this gap by enabling a more precise understanding of treatment response, helping teams identify the right patient populations and detect meaningful signals sooner in development. By reducing uncertainty around responder identification and trial design, Lumos AI supports more efficient development programmes and more transparent downstream clinical decision-making.
“We built Lumos AI to address two fundamental questions: which patients are most likely to benefit from a given therapy and which new or existing therapies are most likely to work for a given patient subtype,” said Erwin Estigarribia, CEO of Headlamp Health. “Lumos AI helps pharmaceutical development teams ask better questions earlier by understanding variability rather than relying on volume alone.”
Key features of Lumos AI
Lumos AI supports decision-making across the neuroscience drug development lifecycle, including:
- Responder and non-responder identification: Identifies patient subtypes most likely to benefit from a given therapy.
- Trial strategy refinement: Informs inclusion criteria, study design and enrolment strategy earlier in development.
- Trajectory insight: Models how patients change over time beyond episodic assessments.
- Portfolio decision support: Helps de-risk development programmes and portfolio decisions, particularly in early- and mid-stage trials.
Why now: moving beyond static trial design
Recent advances in AI, combined with access to large-scale longitudinal real-world data, have created an opportunity to move beyond episodic assessments and static trial designs in neuroscience. With Lumos AI, teams gain a longitudinal view of patient response that better reflects how patients change over time.
“Psychiatry has settled for a ‘responder’ definition that effectively means a patient is only 50% less miserable. We wouldn’t accept a 50% reduction in tumour load as a success in oncology and we shouldn’t accept it here,” said Dr. Charles B. Nemeroff, Chair of Psychiatry at UT Austin and Advisor to Headlamp Health. “Headlamp’s approach focuses on remission, getting patients actually well, not just slightly better, by using continuous data to guide them to the right treatment faster.”
The launch of Lumos AI coincides with the addition of Williams and Nemeroff to Headlamp Health’s Board of Advisors, bringing advocacy, clinical and academic perspectives to the company’s work in precision neuroscience.
